TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04130711

Intervention type: OTHER
Group type: OTHER
Intervention: Visual virtual Conditions
Description: The objective is to evaluate if certain virtual visual conditions can increase the illusion of movement induced by the tendon vibration of the upper limb.~Thirty healthy volunteers and 20 post-stroke subjects will test 3 different situations of vibration applications, with no EEG Neurofeedback session. It will be applied to the subject (healthy and post-stroke) according to a randomized order a vibrator for a few minutes on his non-dominant (or deficit) hand hidden from view, with a screen representing a static virtual hand, then a vibrator on his hand hidden with a screen representing an animated virtual hand, then a vibrator on his hand hidden with a screen representing an empty background.

Intervention type: OTHER
Group type: OTHER
Intervention: Standard EEG
Description: Twenty healthy volunteers test 3 separate electroencephalographic recording conditions without Neurofeedback. It will be applied to the subject an EEG headset recording brain activity during the application of vibration stimulation producing the illusion of movement on the non-dominant hand or during a task Mental imagery of the upper limb, or during the joint application of vibratory stimulation and a mental imaging task on the affected upper limb in a randomized order.
Study: NCT03352362

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ibuprofen (caldolor 10 mg / kg)
Description: Dilution caldolor 10 mg / kg in Hartmann solution to 50 mL - 100 mL and intravenous injection for 30 minutes immediately after induction of anesthesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propacetamol (denogan 30 mg / kg)
Description: Dilution denogan 30 mg / kg in the dissolved solution to a total of 10 ml and intravenous injection for 10 minutes after the main surgical procedure end

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ibuprofen + propacetamol
Description: Dilution caldolor 10 mg / kg in Hartmann solution to 50 mL - 100 mL and intravenous injection for 30 minutes immediately after induction of anesthesia Dilution denogan 30 mg / kg in the dissolved solution to a total of 10 ml and intravenous injection for 10 minutes after the main surgical procedure end
Study: NCT04802694

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Water-based barrier tape
Description: The infants in experiment 1 group will be applied water-based barrier tape. The area will be covered by water-based barrier tape to fix nasogastric tube and after waiting 1 minute for drying up it will be fastened by silk tape used in clinic. The silk tape will be 5 cm long and it will be changed in every 24 hours. Following the removal of silk tape on the water-based barrier tape, the skin integrity of the infants will be evaluated through Neonatal Skin Condition Score Scale and the score will be recorded in the chart. Water-based barrier tape will be applied to the area every time the plaster will be changed and current skin condition score will be noted to the chart.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hydrocolloid barrier tape
Description: As for experiment 2 group, hydrocolloid barrier tape will be used to fix the nasogastric tube. The hydrocolloid barrier tape, which was cut and shaped appropriately beforehand, will be applied to the area in order to stabilize the nasogastric tube and the tube will be stabilized with silk tape used in clinic. The silk tape will be 5 cm long and it will be changed in every 24 hours. Following the removal of silk tape on the hydrocolloid barrier tape, the skin integrity of the infants will be evaluated through Neonatal Skin Condition Score Scale . Since the hydrocolloid barrier tape can stay on the skin for 7 days and be transparent, the assessment of skin condition will be realized for 7 days and noted down to the chart.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Silk tape
Description: The silk tape used in clinic routinely will be used for control group infants to fix the nasogastric tube without any barrier. The silk tape will be 5cm long and it will be changed in every 24 hours. Following the removal of silk tape, the skin integrity of the infants will be evaluated through Neonatal Skin Condition Score Scale and the score will be recorded in the chart.
Study: NCT00003470

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antineoplaston therapy (Atengenal + Astugenal)
Description: Adults with an anaplastic astrocytoma that has not responded to standard therapy will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1.
Study: NCT06559111

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 2-week casting followed by 4-week bracing
Description: Participants in the bracing group had a cast for 2 weeks after the surgery followed by ankle brace for 4 weeks.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 6-week casting
Description: Participants in the casting group had a cast for 6 weeks after the surgery.
Study: NCT03646175

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Choline
Description: Participants will consume 1000 mg (2x500 mg) of choline bitartrate (over-the-counter supplement) between 10PM and 12AM the evening before the scheduled testing session and arrive fasted to the laboratory. There will be 2 testing sessions separated by 1 week.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will consume 1000 mg (2x500 mg) of placebo between 10PM and 12AM the evening before the scheduled testing session and arrive fasted to the laboratory. There will be 2 testing sessions separated by 1 week.
Study: NCT00840606

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BUSPAR® 30 mg Tablet
Description: 1 x 30 mg, single-dose fasting

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buspirone Hydrochloride 30 mg Tablet
Description: 1 x 30 mg, single-dose fasting
Study: NCT04876157

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Artificial intelligence-aimed point-of-care ultrasound image interpretation system
Description: improve the sensitivity and specificity of the AI-aimed ultrasound interpretation system
Study: NCT00398983

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: 20 mg/m\^2 IV over 1 hour daily for 5 days
Study: NCT04084080

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Red Blood Cell
Description: Red blood cell exchange transfusions will be performed every 3-6 weeks to maintain a target post-transfusion hemoglobin S level of \<20% and a pre-transfusion hemoglobin S of \<30%.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of care
Description: NHLBI/ASH/ATS Expert Panel recommended guidelines

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: NHLBI/ASH/ATS Expert Panel recommended guidelines
Study: NCT01937234

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoclopramide
Description: Intravenous injection of 10mg metoclopramide, at enrollment, then every 2 hours.~Maximum of 3 doses.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous injection of 0.9% sodium chloride, at enrollment, then every 2 hours.~Maximum of 3 doses.
Study: NCT01499602

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LNG-IUS; Mirena; Bayer Schering Pharma Oy, Finland
Description: Initial release rate of 20µg Levonorgestrel per day for one year follow up.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norethisterone Acetate tablets
Description: Norethisterone Acetate tablets at a dose of 5 mg three times daily (15mg/day) for 3 weeks over three months.With persistence of endometrial hyperplasia, the treatment is repeated for another 3 months
Study: NCT02364713

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine Hydrochloride
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter
Description: Given IP

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegylated Liposomal Doxorubicin Hydrochloride
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topotecan Hydrochloride
Description: Given IV
Study: NCT03948503

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mulligan concept
Description: Mobilization with movement during an active dorsi-flexion of the ankle

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sham mobilization with movement during an active dorsi-flexion of the ankle
Study: NCT01270594

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: COPD Inhaler Counseling
Description: The counseling will be performed via telephone by a pharmacist at the William S Middleton Memorial Veterans Hospital. The counseling will include education about inhaled COPD medication, inhaler technique review, reminder tools, and motivational interviewing.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Usual Pharmacy Care
Description: The usual care arm will receive standard care from the William S Middleton Memorial Veterans Hospital pharmacists.
Study: NCT04559503

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Progressive relaxation exercises
Description: Progressive relaxation exercises are those involving the voluntary, regular and consecutive relaxation of the muscles until there is relaxation all over the body. PMR are consisted of taking a deep breath and then tensing and relaxing muscles in both hands and arms, shoulders, chest, abdomen, hips, legs, feet, and face regions. The training was given in line with the CD that was prepared by the Turkish Psychologists Association as three-part relaxation exercises. The first part of the CD contains the definition, purpose and applications to consider when doing the exercises and a definition of 10-minute deep relaxation. In the second 30-minute section, relaxation exercises are explained accompanied by the sound of streams and oral instructions. The last section, which consists of 30 minutes, contains only relaxation music without instructions.
Study: NCT02756663

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: panobinostat (capsules)
Description: Panobinostat capsules, oral: 10mg, 15mg, 20mg dosing 3x a week, 1 week on / 1 week off, in a 4 week cycle (28 days). Treatment arm A: only capsules of 10mg will be used Treatment arm B: capsules of 10mg and 15mg are foreseen for dose reduction only.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: panobinostat (capsules)
Description: Panobinostat capsules, oral: 10mg, 15mg, 20mg dosing 3x a week, 1 week on / 1 week off, in a 4 week cycle (28 days). Treatment arm A: only capsules of 10mg will be used Treatment arm B: capsules of 10mg and 15mg are foreseen for dose reduction only.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carfilzomib (infusion)
Description: Carfilzomib infusion; 20 mg/m2 i.v. on C1D1 and C1D2; 56 mg/m2 i.v. on subsequent dosing days (2x a week; 3 weeks on/1 weeks off ); 4 week cycle (28 days)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carfilzomib (infusion)
Description: Carfilzomib infusion; 20 mg/m2 i.v. on C1D1 and C1D2; 56 mg/m2 i.v. on subsequent dosing days (2x a week; 3 weeks on/1 weeks off ); 4 week cycle (28 days)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carfilzomib (infusion)
Description: Carfilzomib infusion; 20 mg/m2 i.v. on C1D1 and C1D2; 56 mg/m2 i.v. on subsequent dosing days (2x a week; 3 weeks on/1 weeks off ); 4 week cycle (28 days)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone (tablets)
Description: Dexamethasone tablets p.o. 20 mg on days of carfilzomib infusion (2x week) and on D22 and D23 of each 4 week cycle (28 days)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone (tablets)
Description: Dexamethasone tablets p.o. 20 mg on days of carfilzomib infusion (2x week) and on D22 and D23 of each 4 week cycle (28 days)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexamethasone (tablets)
Description: Dexamethasone tablets p.o. 20 mg on days of carfilzomib infusion (2x week) and on D22 and D23 of each 4 week cycle (28 days)
Study: NCT02577458

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CM082
Description: CM082 tablets taken orally once a day on 28-day cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Everolimus tablets taken orally once a day on 28-day cycles
Study: NCT01349218

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood sample drawn from a vein
Description: 0.5 ml will be drawn from a vein when an IV is started for the surgery or from an IV already in place. The blood will be placed into a heparinized, 1 ml syringe for venous blood gas analysis.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood sample drawn from a heel stick
Description: A second blood sample, 0.3 ml will be drawn into a capillary pipette from a heel stick for capillary blood gas analysis.
Study: NCT01906164

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALS-008176

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01120197

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise group
Description: Weekly exercises

Intervention type: OTHER
Group type: OTHER
Intervention: Control Group
Description: No Intervention, control group only
Study: NCT02305615

Intervention type: OTHER
Intervention: Bevacizumab
Description: Bevacizumab at a dose and schedule according to approved label and SmPC. The recommended dose of bevacizumab, administered as an intravenous infusion, is either 5 milligrams per kilogram (mg/kg) or 10 mg/kg of body weight given once every 2 weeks or 7.5 mg/kg or 15 mg/kg of body weight given once every 3 weeks. Bevacizumab is always used in combination with chemotherapy for the treatment of participants with metastatic CRC. It is recommended that treatment be continued until progression of the underlying disease or until unacceptable toxicity.

Intervention type: COMBINATION_PRODUCT
Intervention: Chemotherapy
Description: Fluoropyrimidine-based doublet chemotherapy (5-Fluorouracil \[5-FU\] or capecitabine plus oxaliplatin or irinotecan) as first-line treatment; and continued fluoropyrimidine treatment with or without treatment modification for oxaliplatin or irinotecan, as per treating physician discretion.
Study: NCT02826551

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Marcaine
Description: Pain control medication to theoretically reduce the amount of posterior knee pain that is common after ACL surgery by placing the injection into the posterior capsule of the knee during surgery. This is very easy and safe to accomplish as the surgeon will have direct visualization of the posterior capsule during the surgery.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ice

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Ice

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Percocet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Percocet
Study: NCT04175977

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aliviado Dementia Care-Hospice Edition QAPI program
Description: Multi-modal QAPI program for improving the quality of care provided to PWD and support to their informal caregivers through hospice. It has been culturally tailored for use in diverse settings and tested with multiple minority communities in New York, including multiple Hispanic groups and African-Americans and Caribbean blacks. The intervention includes mentorship, training, a toolkit, and mobile app to assist clinicians in providing evidence-based symptom management to persons with dementia.
Study: NCT01336101

Intervention type: DEVICE
Group type: OTHER
Intervention: EPIC™ Self-Expanding Nitinol Vascular Stent
Description: SFA/Popliteal Artery stenting
Study: NCT03906877

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acid hyaluronic injection laryngoplasty
Description: Hyaluronic acid is injected into the paralyzed vocal fold

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Voice therapy
Description: 15 sessions of thirty minutes of voice therapy, twice a week, and home practice.~This voice management will be specific to unilateral vocal fold paralysis and will focus on three objectives: reinforcement of the vocal muscle, glottal closure and glottal opening. These three objectives will be worked through different vocal exercises (on voiced phonemes) and breathing exercises
Study: NCT04130711

Intervention type: OTHER
Group type: OTHER
Intervention: Neurofeedback Training Stroke Patients
Description: The post-stroke subject is evaluated on clinical tests (FMA, ARAT, MAL, NHPT, Finger Tapping test) during the first visit. Then, he performs 12 sessions of NFB (on his deficit member) lasting 45 minutes, spread over 6 weeks, depending on the feedback modality that has been drawn randomly (visual or visuo-vibratory). A second visit after the first NFB session and a third visit after the last NFB session evaluates the motor skills of the trained upper limb (FMA, ARAT, MAL, NHPT, Finger Tapping test) and a satisfaction questionnaire is given to the subject for evaluate tolerance and satisfaction with the feedback modality assigned. Evaluation of changes of EEG sensorimotor rhythms at the end of the program.
Study: NCT02268318

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 1-Fermented Dairy Product with Phytosterols (test)
Description: 1- 1 bottle of test product/day
Study: NCT03906877

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham of injection
Description: Injection of physiological saline under the skin of the neck (sham of injection).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sham of injection
Description: Injection of physiological saline under the skin of the neck (sham of injection).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sham of voice therapy
Description: 15 sessions of thirty minutes of voice therapy, twice a week, and home practice.~This voice management will not be specific to UVFP but may allow patients to improve their vocal gesture.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham of voice therapy
Description: 15 sessions of thirty minutes of voice therapy, twice a week, and home practice.~This voice management will not be specific to UVFP but may allow patients to improve their vocal gesture.
Study: NCT02242396

Intervention type: DRUG
Intervention: Telmisartan

Intervention type: DRUG
Intervention: Telmisartan hydrochlorothiazide
Study: NCT04175977

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: Usual care as provided by the hospice agency

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: Usual care as provided by the hospice agency

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: Usual care as provided by the hospice agency

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: Usual care as provided by the hospice agency

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: Usual care as provided by the hospice agency

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: Usual care as provided by the hospice agency

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: Usual care as provided by the hospice agency
Study: NCT02947750

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise training
Description: Participants will exercise 3 times a week on a stationary ergometer. Exercise intensity will begin at low levels (50% of maximal heart rate reserve) calculated utilizing the Karvonen method. Briefly, target exercise heart rate (HR) is calculated by subtracting the persons age from 220. Resting heart rate is then subtracted from this number. The answer is then multiplied by the target percent (50% for example) and the product is added back to resting heart rate to provide the target exercise session heart rate. Intensity will be increased by 5% every week (as tolerated by the participant) to a maximum of 80% of maximal heart rate. Exercise time will progress from an initial 20 minutes per session to a maximum of 45 minutes by increasing 5 minutes each week.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stretching
Description: Participants randomized to 'No Exercise Training' group will instead of aerobic exercise, undergo progressive whole body stretching and toning exercises designed for individuals 65 and older. This type of low intensity activity is designed not to increase heart rate and will serve as the Control group to the Exercise Training group. The Control group will come in for stretching sessions 3 times per week for 20-45 minutes.
Study: NCT02826551

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Knee Brace and Crutches
Study: NCT02947750

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Stretching
Description: Participants randomized to 'No Exercise Training' group will instead of aerobic exercise, undergo progressive whole body stretching and toning exercises designed for individuals 65 and older. This type of low intensity activity is designed not to increase heart rate and will serve as the Control group to the Exercise Training group. The Control group will come in for stretching sessions 3 times per week for 20-45 minutes.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Histidine and beta-alanine supplementation
Description: Histidine and beta-alanine are two over-the-counter supplements commonly used to enhance sports performance in athletes. Participants randomized to this study arm will receive combined histidine (4g/day) and beta-alanine (3.2g/day) supplementation.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Histidine and beta-alanine placebo
Description: Participants randomized to this study arm will receive a placebo to match combined histidine (4g/day) and beta-alanine (3.2g/day) supplementation.
Study: NCT02826551

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Knee Brace and Crutches
Study: NCT04175977

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: Usual care as provided by the hospice agency